BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26456572)

  • 1. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
    Yau C; Meyer L; Benz S; Vaske C; Scott G; Egan B; Labhart P; Pourmand N; Benz CC
    Breast Cancer Res Treat; 2015 Nov; 154(1):23-32. PubMed ID: 26456572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
    Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
    Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers.
    Yau C; Wang Y; Zhang Y; Foekens JA; Benz CC
    Breast Cancer Res Treat; 2011 Apr; 126(3):803-10. PubMed ID: 21225456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.
    Sanders DA; Ross-Innes CS; Beraldi D; Carroll JS; Balasubramanian S
    Genome Biol; 2013 Jan; 14(1):R6. PubMed ID: 23347430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor-positive breast cancer.
    Ahn H; Sim J; Abdul R; Chung MS; Paik SS; Oh YH; Park CK; Jang K
    J Korean Med Sci; 2015 Apr; 30(4):390-7. PubMed ID: 25829806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer.
    Yang C; Chen H; Yu L; Shan L; Xie L; Hu J; Chen T; Tan Y
    Cancer Gene Ther; 2013 Feb; 20(2):117-24. PubMed ID: 23306612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy.
    Wolter P; Hanselmann S; Pattschull G; Schruf E; Gaubatz S
    Oncotarget; 2017 Feb; 8(7):11160-11172. PubMed ID: 28061449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
    Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
    Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells.
    Madureira PA; Varshochi R; Constantinidou D; Francis RE; Coombes RC; Yao KM; Lam EW
    J Biol Chem; 2006 Sep; 281(35):25167-76. PubMed ID: 16809346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
    Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
    Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.
    Szekely B; Iwamoto T; Szasz AM; Qi Y; Matsuoka J; Symmans WF; Tokes AM; Kulka J; Swanton C; Pusztai L
    Breast Cancer Res Treat; 2013 Apr; 138(3):691-8. PubMed ID: 23504136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
    Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
    Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.
    Millour J; de Olano N; Horimoto Y; Monteiro LJ; Langer JK; Aligue R; Hajji N; Lam EW
    Mol Cancer Ther; 2011 Jun; 10(6):1046-58. PubMed ID: 21518729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
    Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
    Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
    Ahmad A; Wang Z; Kong D; Ali S; Li Y; Banerjee S; Ali R; Sarkar FH
    Breast Cancer Res Treat; 2010 Jul; 122(2):337-46. PubMed ID: 19813088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-coding single nucleotide variants affecting estrogen receptor binding and activity.
    Bahreini A; Levine K; Santana-Santos L; Benos PV; Wang P; Andersen C; Oesterreich S; Lee AV
    Genome Med; 2016 Dec; 8(1):128. PubMed ID: 27964748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer.
    Horimoto Y; Hartman J; Millour J; Pollock S; Olmos Y; Ho KK; Coombes RC; Poutanen M; Mäkelä SI; El-Bahrawy M; Speirs V; Lam EW
    Am J Pathol; 2011 Sep; 179(3):1148-56. PubMed ID: 21763263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
    Katzenellenbogen BS; Guillen VS; Katzenellenbogen JA
    Breast Cancer Res; 2023 Jun; 25(1):76. PubMed ID: 37370117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.